Public Health Impact of Paxlovid as Treatment for COVID-19, United States
Version 3 2024-06-14, 10:08
Version 2 2024-05-30, 15:43
Version 1 2024-03-14, 04:32
journal contribution
posted on 2024-06-14, 10:08 authored by Y Bai, Z Du, L Wang, Eric LauEric Lau, ICH Fung, P Holme, BJ Cowling, AP Galvani, RM Krug, LA MeyersPublic Health Impact of Paxlovid as Treatment for COVID-19, United States
History
Related Materials
- 1.
Location
Atlanta, Ga.Language
engPublication classification
C1.1 Refereed article in a scholarly journalJournal
Emerging Infectious DiseasesVolume
30Pagination
262-269ISSN
1080-6040eISSN
1080-6059Issue
2Publisher
Centers for Disease Control and PreventionPublication URL
Usage metrics
Categories
Keywords
Antiviral AgentsCOVID-19Drug CombinationsHumansLactamsLeucineNitrilesProlinePublic HealthRitonavirSARS-CoV-2United Statescoronavirus diseasemathematical modelPaxlovidpublic health impactrespiratory infectionsSARS-CoV-2 transmissionsevere acute respiratory syndrome coronavirus 2treatmentviruseszoonoses
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC